liver cancer

[Proceedings of the National Academy of Sciences of the United States of America] For key structural factors within the nucleus and ECM, the authors discovered specific gene-gene scaling exponents across many of the 32 tumor types in The Cancer Genome Atlas, and they demonstrated utility in predicting patient survival as well as scaling-informed machine learning.

[BMC Cancer] A higher matrix stiffness equipped tumor cells with enhanced stemness and proliferative characteristics, which was dependent on the activation of integrin β1/FAK/ERK1/2/NF-κB signaling pathway.

[Gilead Sciences, Inc.] Gilead Sciences, Inc. announced that it has submitted a Biologics License Application to the US FDA for bulevirtide for injection, a potential first-in-class antiviral medicine for the treatment of chronic hepatitis delta virus infection in adults with compensated liver disease.

[Nature Communications] Scientists identified and characterized a remarkable mutational mechanism in human hepatocellular carcinoma caused by Hepatitis B virus, by which DNA molecules from the virus were inserted into the tumor genome causing dramatic changes in its configuration, including non-homologous chromosomal fusions, dicentric chromosomes and megabase-size telomeric deletions.

[Communications Biology] Researchers performed whole-genome sequencing on clonally expanded single liver stem cells cultured as intrahepatic cholangiocyte organoids from patients with alcoholic cirrhosis, non-alcoholic steatohepatitis, and primary sclerosing cholangitis.

[Singapore Health Sciences Authority] Singapore-based SCG Cell Therapy Pte Ltd has signed an agreement with the Cell Therapy Facility of Singapore Health Sciences Authority for the evaluation and validation of SCG’s proprietary cell therapy manufacturing process to develop a new treatment option for patients with Hepatitis B virus related hepatocellular carcinoma.